INCY logo

Incyte Genomics Inc

INCY

INCY: Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

more

Show INCY Financials

All
Government
Consumer Interest
SEC Filings
ESG/Other

Recently reported changes by institutional investors

Quarterly net insider trading by INCY's directors and management

Government lobbying spending instances

  • $220,000 Jul 20, 2023 Issue: Medicare/Medicaid
  • $350,000 Apr 20, 2023 Issue: Medicare/Medicaid
  • $180,000 Jan 20, 2023 Issue: Copyright/Patent/Trademark Medicare/Medicaid
  • $220,000 Oct 20, 2022 Issue: Copyright/Patent/Trademark Medicare/Medicaid
  • $200,000 Jul 21, 2022 Issue: Taxation/Internal Revenue Code Medicare/Medicaid
  • $280,000 Apr 20, 2022 Issue: Medicare/Medicaid
  • $110,000 Jan 21, 2022 Issue: MEDICARE/MEDICAID
  • $190,000 Oct 20, 2021 Issue: MEDICARE/MEDICAID
  • $500,000 Jul 20, 2021 Issue: MEDICARE/MEDICAID
  • $200,000 Apr 20, 2021 Issue: MEDICARE/MEDICAID
  • $50,000 Jan 21, 2021 Issue: Health Issues
  • $50,000 Jan 20, 2021 Issue: None
  • $20,000 Jan 19, 2021 Issue: None
  • $50,000 Oct 20, 2020 Issue: Health Issues
  • $50,000 Oct 20, 2020 Issue: MEDICARE/MEDICAID
  • $50,000 Jul 20, 2020 Issue: MEDICARE/MEDICAID
  • $50,000 Jul 20, 2020 Issue: Medicare/Medicaid
  • $50,000 Apr 27, 2020 Issue: MEDICARE/MEDICAID
  • $50,000 Apr 17, 2020 Issue: Medicare/Medicaid
  • $30,000 Jan 21, 2020 Issue: MEDICARE/MEDICAID
  • $30,000 Jan 18, 2020 Issue: Medicare/Medicaid
  • $20,000 Mar 26, 2003 Issue: Copyright/Patent/Trademark
  • $20,000 Aug 22, 2002 Issue: Copyright/Patent/Trademark
  • $20,000 Mar 14, 2002 Issue: Copyright/Patent/Trademark
  • $60,000 Feb 20, 2002 Issue: None
  • $20,000 Sep 28, 2001 Issue: Copyright/Patent/Trademark
  • $60,000 Feb 15, 2000 Issue: Medical/Disease Research/Clinical Labs
  • $40,000 Aug 16, 1999 Issue: Medical/Disease Research/Clinical Labs
U.S. Patents

New patents grants

  • Patent Title: Carboxamide compounds and uses thereof Aug. 22, 2023
  • Patent Title: Alk2 inhibitors for the treatment of anemia Aug. 15, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Aug. 08, 2023
  • Patent Title: Tricyclic heterocyclic compounds as sting activators Aug. 01, 2023
  • Patent Title: 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins Jul. 18, 2023
  • Patent Title: Naphthyridinone compounds as jak2 v617f inhibitors Jul. 04, 2023
  • Patent Title: Processes of preparing a jak1 inhibitor Jun. 27, 2023
  • Patent Title: Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors Jun. 13, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Jun. 13, 2023
  • Patent Title: Bicyclic heterocycles as fgfr4 inhibitors Jun. 06, 2023
  • Patent Title: Tricyclic urea compounds as jak2 v617f inhibitors May. 30, 2023
  • Patent Title: Methods of treating cancer with an fgfr inhibitor Apr. 18, 2023
  • Patent Title: Biomarkers for vitiligo Apr. 11, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Mar. 28, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Mar. 21, 2023
  • Patent Title: Bicyclic heterocycles as fgfr inhibitors Mar. 21, 2023
  • Patent Title: Topical treatment of vitiligo by a jak inhibitor Mar. 14, 2023
  • Patent Title: Pd-l1/sting conjugates and methods of use Mar. 07, 2023
  • Patent Title: Jak1 pathway inhibitors for the treatment of gastrointestinal disease Mar. 07, 2023
  • Patent Title: Pyrrolotriazine compounds as tam inhibitors Feb. 28, 2023
  • Patent Title: Bicyclic heterocycles as fgfr inhibitors Feb. 28, 2023
  • Patent Title: Topical treatment of vitiligo by a jak inhibitor Feb. 28, 2023
  • Patent Title: Topical formulation for a jak inhibitor Feb. 28, 2023
  • Patent Title: Bipyrazole derivatives as jak inhibitors Feb. 28, 2023
  • Patent Title: Ruxolitinib formulation for reduction of itch in atopic dermatitis Feb. 28, 2023
  • Patent Title: Biomarkers for inflammatory skin disease Feb. 21, 2023
  • Patent Title: Sustained-release dosage forms of ruxolitinib Feb. 14, 2023
  • Patent Title: Sustained-release dosage forms of ruxolitinib Feb. 14, 2023
  • Patent Title: Topical formulation for a jak inhibitor Feb. 07, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Feb. 07, 2023
  • Patent Title: Bicyclic heterocycles as fgfr inhibitors Jan. 31, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Jan. 31, 2023
  • Patent Title: Pyrazolopyrimidine compounds and uses thereof Jan. 03, 2023
  • Patent Title: Heterocyclic compounds as immunomodulators Dec. 27, 2022
  • Patent Title: Bicyclic heterocycles as fgfr inhibitors Dec. 20, 2022
  • Patent Title: Spiro compounds as inhibitors of kras Dec. 20, 2022
  • Patent Title: Salts of an lsd1 inhibitor and processes for preparing the same Nov. 29, 2022
  • Patent Title: Ruxolitinib formulation for reduction of itch in atopic dermatitis Nov. 29, 2022
  • Patent Title: Salts of a pim kinase inhibitor Nov. 22, 2022
  • Patent Title: Salts of an lsd1 inhibitor Nov. 15, 2022
  • Patent Title: Tricyclic heterocycles as bet protein inhibitors Nov. 15, 2022
  • Patent Title: Indazole compounds and uses thereof Nov. 08, 2022
  • Patent Title: Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors Oct. 18, 2022
  • Patent Title: Crystalline forms of a fgfr inhibitor and processes for preparing the same Oct. 18, 2022
  • Patent Title: Solid forms of an fgfr inhibitor and processes for preparing the same Oct. 11, 2022
  • Patent Title: Heterocyclic compounds as immunomodulators Oct. 11, 2022
  • Patent Title: Imidazopyridazine and imidazopyridine compounds and uses thereof Oct. 04, 2022
  • Patent Title: Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same Sep. 27, 2022
  • Patent Title: Tricyclic amine compounds as cdk2 inhibitors Sep. 20, 2022
  • Patent Title: Tricyclic amine compounds as cdk2 inhibitors Sep. 13, 2022
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of INCY in WallStreetBets Daily Discussion

INCY News

Recent insights relating to INCY

CNBC Recommendations

Recent picks made for INCY stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in INCY

Corporate Flights

Flights by private jets registered to INCY